Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).

Although the difference between tenapanor and placebo did not reach statistical significance in terms of the ≥6 of 12 treatment week CSBM responder rate, it is notable that statistical significance was achieved for the more stringent endpoints requiring ≥9 of 12 treatment weeks of CSBM response.

also in 111,027 other papers